$IRD News

Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026

BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy

Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29

Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13

HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases - Slideshow

Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price Target

Opus Genetics Files Prospectus For Offering 2.679M Common Shares On Behalf Of Selling Shareholders

Guggenheim Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $16

Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform

Leerink Partners Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10

Citizens Maintains Market Outperform on Opus Genetics, Lowers Price Target to $11

Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate

Opus Genetics Announces New Clinical And Preclinical Data From Multiple Programs Presented At Association For Research In Vision And Opthalmology Annual Meeting May 3-7

Opus Genetics' OPGx-LCA5 Program Accepted Into FDA's Rare Disease Evidence Principles Program

Citizens Initiates Coverage On Opus Genetics with Market Outperform Rating, Announces Price Target of $12

Opus Genetics Secures Up To $155M Non-Dilutive Financing From Oberland Capital Plus 1.1M Shares At $4.48 To Advance Inherited Retinal Disease Gene Therapy Pipeline

Opus Genetics Secures Up To $155M Non-Dilutive Financing From Oberland Capital Plus 1.1M Shares At $4.48 To Advance Inherited Retinal Disease Gene Therapy Pipeline